Matinas BioPharma Hlds

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The firm's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers a broad-spectrum fungicidal agent, amphotericin B, and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded by Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Matinas BioPharma advances MAT2203, faces financial challenges, and extends cash runway

Matinas BioPharma's progress on MAT2203 and positive feedback position the company well in the infectious disease treatment market.
Financially, the company faces challenges with no revenue, high expenses, and a need to carefully manage cash reserves for sustained operations.
Opportunities lie in advancing MAT2203 towards Phase III trials, exploring new therapeutic areas, and extending cash runway for future growth.
Overall, Matinas BioPharma's focus on innovation and strategic partnerships sets the stage for potential growth and market leadership in infectious disease treatments.

Matinas BioPharma reports improved Q2 performance and advances key drug programs

Matinas BioPharma's Q2 2024 performance reflects improved cost management and financial stability, supported by a strengthened cash position and ongoing progress in key drug development programs.
While challenges persist in revenue generation and trial timelines, the company's strategic strengths in product pipeline expansion and innovation present opportunities for future growth and market success.
Overall, Matinas BioPharma's focus on advancing key drug candidates and addressing clinical needs in fungal infections positions the company for potential revenue growth and market leadership in the pharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

BEDMINSTER, N.J., Jan.  14, 2020  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing  of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma.

Matinas BioPharma Announces Closing of Public Offering of Common Stock

The company announced the pricing of a public stock offering.

Here's Why Matinas Biopharma Shares Fell as Much as 23.6% Today

BEDMINSTER, N.J., Jan.  10, 2020  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing of its underwritten registered public offering of 32,260,000 shares of its common stock, offered at a price to the public of $1.55 per share for expected gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Matinas BioPharma has granted the underwriters a 30-day option to purchase up to an additional 4,839,000 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Matinas BioPharma. The offering is expected to close on or about January 14, 2020, subject to customary closing conditions.

Matinas BioPharma Announces Pricing of Public Offering of Common Stock

BEDMINSTER, N.J., Jan.  09, 2020  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (“Matinas BioPharma” or the “Company”) -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In connection with the offering, Matinas BioPharma intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. All of the shares to be sold in the offering are to be sold by Matinas BioPharma.

Matinas BioPharma Announces Proposed Public Offering of Common Stock

The small-cap pharma sank on an update from its top competitor.

Here's Why Matinas BioPharma Shares Lost as Much as 16.9% Today

Amarin Corporation Plc

Matinas And Amarin, And Other News And Issues: The Good, Bad, And Ugly Of Biopharma

Iteris

OrganiGram Holdings Inc.

Ovid Therapeutics

Plug Power

Snapping up strong buy stocks with great long-term growth prospects doesn’t have to cost you your entire savings.
The post 5 Strong Buy Stocks Under $5 With Massive Upside Potential appeared first on InvestorPlace.

5 Strong Buy Stocks Under $5 With Massive Upside Potential

Good news for its competitor Amarin has investors nervous about Matinas' cardiovascular disease drug MAT9001.

Why Matinas BioPharma Tumbled 13.4% Today

BEDMINSTER, N.J., Dec.  12, 2019  (GLOBE NEWSWIRE) --  Matinas BioPharma Holdings, Inc.  (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group. This feasibility evaluation will involve the development of oral formulations using Matinas’ lipid nano-crystal (LNC) platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules.

Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

BEDMINSTER, N.J., Nov.  18, 2019  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has been invited to present a company overview, as well as host investor meetings, at the 31st Annual Piper Jaffray Healthcare Conference.

Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q3 2019 Results - Earnings Call Transcript

Liver Therapy Forum weekly digest provides an overview of therapeutics in development for hypertriglyceridemia in 2019. The focus this week is on Matinas BioPharma.

Matinas BioPharma And Amarin In Hypertriglyceridemia: The Head-To-Head Phase 2 Study

BEDMINSTER, N.J., Oct.  14, 2019  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenance therapy in HIV-patients with cryptococcal meningitis, a life-threatening fungal infection most commonly observed in immunocompromised individuals.

Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis

BEDMINSTER, N.J., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the 2019 Cantor Global Healthcare Conference.

Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference

BEDMINSTER, N.J., Sept.  25, 2019  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic (PD) study of MAT9001 against Vascepa in patients with elevated triglycerides (150-499 mg/dL).

Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®

BEDMINSTER, N.J., Aug.  28, 2019  (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the H.C. Wainwright 21st Annual Global Investment Conference.

Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q2 2019 Results - Earnings Call Transcript

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 25.00% and 50.00%, respectively, for the quarter ended June 2019.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week?

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q1, 2019 Results - Earnings Call Transcript

Matinas BioPharma Holdings, Inc. (MTNB) CEO Jerry Jabbour on Q4 2018 Results - Earnings Call Transcript

News for Matinas BioPharma Hlds Stock (MTNB)